AspenBio Pharma, an in vitro diagnostic company, focuses on the clinical development and commercialization of its lead product, AppyScore, a blood-based test with projected high sensitivity and negative predictive value that is designed to aid in the identification of patients at low risk for acute appendicitis. AppyScore’s initial application is for pediatric, adolescent and young adult patients with abdominal pain. For more information visit the company’s Web site at: www.aspenbiopharma.com.

Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital’s management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. For more information on Aegis Capital, visit www.aegiscapcorp.com.

Let us hear your thoughts below: